![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
◽Dr. Angela DeMichele gave a brilliant discussion of the abstract with important considerations;
◽First big point:
👉 we don't have mature survival data to prove that early switching will benefit patients in the long term.
⬇️⬇️
@OncoAlert @ASCO #ASCO25
#ASCO25 | Lung Cancer | 9 AM today | Aerie Crown Theater | Sukhmani Padda presents Lung-MAP S1900E | Impact of co-mutations TP53 and STK11 on efficacy of sotorasib in patients w KRAS G12C mutant NSCLC | ECOG-ACRIN @EAonc @SWOG @Foxchase @theNCI @CancerResearch | Abstract 8518
Outstanding work led by @CoulterBME PhD student Sebastian Medina @WinshipAtEmory @EmoryUniversity on a pathology #AI signature showing predictive benefit of docetaxyl in high risk localized & metastatic prostate cancer @ASCO 2025. Collaboration with @eaonc @RTOGFoundation
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
37
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
